Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.46-53,8.DOI:10.1016/j.pharp.2026.03.006
Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China
Kaijie Yao 1Yun Bao 2Ying Chen 1Yan Zhong 3Mengxia Yan 4Wen Li 5Bin Wu1
作者信息
- 1. Department of Pharmacy,Shanghai Chest Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200030,China
- 2. West China School of Pharmacy,Sichuan University,Chengdu,610041,China Institute of Clinical Research and Evidence Based Medicine,Gansu Provincial Hospital,Lanzhou,730000,China
- 3. Policy Research Office,Health Management Centre,China Human Health Science and Technology Promotion Association,Beijing,100010,China
- 4. Department of Pharmacy,Ningbo Hangzhou Bay Hospital,Ningbo,Zhejiang,315336,China
- 5. Department of Pharmacy,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200127,China
- 折叠
摘要
关键词
Cost‑effectiveness analysis/Bevifibatide/Eptifibatide/Acute coronary syndrome/Percutaneous coronary intervention分类
医药卫生引用本文复制引用
Kaijie Yao,Yun Bao,Ying Chen,Yan Zhong,Mengxia Yan,Wen Li,Bin Wu..Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China[J].Pharmacoeconomics and Policy,2026,2(1):P.46-53,8.
